DYN investors have the opportunity to join the Dyne Therapeutics, Inc. fraud investigation with Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims of violations of the securities laws on behalf of investors in Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN).

The investigation is focused on whether the company made false and/or misleading statements and/or failed to disclose relevant information to investors. Dyne issued a press release on September 3, 2024, announcing “new clinical data from its ongoing Phase 1/2 DELIVER study of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) where exon 51 skipping demonstrated unprecedented dystrophin expression and functional improvement in multiple cohorts.” Despite this news, the company announced in a second press release on the same press release that its CMO, COO, and CBO were “resigning from their positions.” Due to this news, Dyne shares plummeted 30.7%, hurting investors.